Similarly, galectin-9 mRNA expression levels tended to be higher in AML and high-risk MDS at diagnosis compared to lower risk MDS (mean fold-change increase ± SD, 2.44 ± 1.8 vs. 1.10 ± 0.9, AML and high-risk vs. lower-risk MDS; p = 0.0722) (Figure 3E). The gene discussed is LGALS9; the disease is myelodysplastic syndrome.